PharmacyCodes



Loracarbefum [INN-Latin] en es it fr

Loracarbefum [INN-Latin] Brand names, Loracarbefum [INN-Latin] Analogs

Loracarbefum [INN-Latin] Brand Names Mixture

  • No information avaliable

Loracarbefum [INN-Latin] Chemical_Formula

C3F8

Loracarbefum [INN-Latin] RX_link

http://www.rxlist.com/cgi/generic3/definity.htm

Loracarbefum [INN-Latin] fda sheet

Loracarbefum_[INN-Latin] FDA

Loracarbefum [INN-Latin] msds (material safety sheet)

Loracarbefum_[INN-Latin] MSDS

Loracarbefum [INN-Latin] Synthesis Reference

No information avaliable

Loracarbefum [INN-Latin] Molecular Weight

188.019 g/mol

Loracarbefum [INN-Latin] Melting Point

-147.6 oC

Loracarbefum [INN-Latin] H2O Solubility

5.7 mg/L

Loracarbefum [INN-Latin] State

Liquid

Loracarbefum [INN-Latin] LogP

2.71

Loracarbefum [INN-Latin] Dosage Forms

Suspension

Loracarbefum [INN-Latin] Indication

Use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

Loracarbefum [INN-Latin] Pharmacology

Perflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, comprised of lipid-coated microspheres filled with octafluoropropane(OFP) gas. It provide contrast enhancement of the endocardial borders during echocardiography. The perflutren lipid microspheres exhibit lower acoustic impedance than blood and enhance the intrinsic backscatter of blood.

Loracarbefum [INN-Latin] Absorption

No information avaliable

Loracarbefum [INN-Latin] side effects and Toxicity

No information avaliable

Loracarbefum [INN-Latin] Patient Information

Loracarbefum [INN-Latin] Organisms Affected

Humans and other mammals